0001209191-22-011338.txt : 20220218 0001209191-22-011338.hdr.sgml : 20220218 20220218164711 ACCESSION NUMBER: 0001209191-22-011338 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220216 FILED AS OF DATE: 20220218 DATE AS OF CHANGE: 20220218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pang Phillip CENTRAL INDEX KEY: 0001787370 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 22653531 MAIL ADDRESS: STREET 1: C/O VIR BIOTECHNOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-16 0 0001706431 Vir Biotechnology, Inc. VIR 0001787370 Pang Phillip C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 1 0 0 Chief Medical Officer Common Stock 2022-02-16 4 M 0 5000 1.53 A 97777 D Common Stock 2022-02-16 4 S 0 5000 31.54 D 92777 D Common Stock 2022-02-17 4 S 0 3009 31.9308 D 89768 D Stock Option (Right to Buy) 1.53 2022-02-16 4 M 0 5000 0.00 D 2028-04-27 Common Stock 5000 52591 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021. Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Howard Horn, Attorney-in-Fact 2022-02-18